Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Taylor, Brackin"'
Autor:
Leighann Litcher-Kelly, Ahmet Ozen, Sarah Ollis, Hagit Baris Feldman, Andrew Yaworsky, Paolo Medrano, Voranush Chongsrisawa, Taylor Brackin, Lorah Perlee, Marisa Walker, Sharanya Pradeep, Michael J. Lenardo, Olivier A. Harari, Jessica J. Jalbert
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-15 (2024)
Abstract Background CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) disease is ultra-rare (
Externí odkaz:
https://doaj.org/article/f82a2fd52091428c9e80233cbb076e5b
Autor:
Kusha A. Mohammadi, Taylor Brackin, Gregory G. Schwartz, Philippe Gabriel Steg, Michael Szarek, Garen Manvelian, Robert Pordy, Sergio Fazio, Gregory P. Geba
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 16859-16868 (2023)
Abstract Objective Assess the risk of new and worsening cancer events among participants who received the lipid‐lowering therapy alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor. Design Pooled post hoc analysis. Setting Six pha
Externí odkaz:
https://doaj.org/article/d27f08a8ad964f6d928013b081b6f41a
Autor:
Marc P. Bonaca, Eric A. Secemsky, Mark R. Nehler, Rupert Bauersachs, Robert W. Yeh, Warren H. Capell, Manesh R. Patel, Sonia S. Anand, Eva Muehlhofer, Lloyd Haskell, Nicholas Govsyeyev, Connie N. Hess, Taylor Brackin, William R. Hiatt, E. Sebastian Debus, Joshua A. Beckman, Fabrizio Fanelli, Laura Mauri, Scott D. Berkowitz
Publikováno v:
Journal of the American College of Cardiology. 78:1768-1778
Background Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality. Objectives This study assessed DCD safety
Autor:
Nicole Jaeger, Marc P. Bonaca, Mark R. Nehler, David Szalay, Henrik Sillesen, Sonia S. Anand, Taylor Brackin, Connie N. Hess, Eva Muehlhofer, Eike Sebastian Debus, William R. Hiatt, David Brasil, Rupert Bauersachs, Warren H. Capell, Manesh R. Patel, Lloyd Haskell, Akos F. Pap, Juraj Madaric, Scott D. Berkowitz
Publikováno v:
Circulation. 142:2219-2230
Background: The VOYAGER PAD trial (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated superiority of rivaroxaban plus aspirin versus aspirin to reduce m
Autor:
Connie N. Hess, Scott D. Berkowitz, E. Sebastian Debus, Dainis Krievins, Patrice Nault, Gabriele Piffaretti, Nicole Jaeger, Fabrizio Fanelli, Franz Hinterreiter, William R. Hiatt, Manesh R. Patel, Marc P. Bonaca, Taylor Brackin, Warren H. Capell, Michael S. Conte, Mark R. Nehler, Henrik Sillesen, Rupert Bauersachs, Lloyd Haskell, Joseph L. Mills, Alexei Svetlikov, Eva Muehlhofer, Nicholas Govsyeyev, Sonia S. Anand
Publikováno v:
Circulation. 144(14)
Background: Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With
Autor:
Connie N, Hess, Manesh R, Patel, Rupert M, Bauersachs, Sonia S, Anand, E Sebastian, Debus, Mark R, Nehler, Fabrizio, Fanelli, Robert W, Yeh, Eric A, Secemsky, Joshua A, Beckman, Laura, Mauri, Nicholas, Govsyeyev, Warren H, Capell, Taylor, Brackin, Scott D, Berkowitz, Eva, Muehlhofer, Lloyd P, Haskell, William R, Hiatt, Marc P, Bonaca
Publikováno v:
Journal of the American College of Cardiology. 78(18)
Paclitaxel drug-coated devices (DCDs) were developed to improve lower extremity revascularization (LER) patency in peripheral artery disease (PAD) but have been associated with long-term mortality.This study assessed DCD safety and effectiveness in L